Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Shareholding

21 Apr 2008 17:43

ReGen Therapeutics PLC21 April 2008 21st April 2008 REGEN THERAPEUTICS PLC ("ReGen" or the "Company"; Ticker: (RGT)) TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii): ReGen Therapeutics Plc 2. Reason for the notification: An acquisition or disposal of voting rights 3. Full name of person(s) subject to the notification obligation (iii): Andrew Clement Wilson 4. Full name of shareholder(s) (if difference from 3): As above 5. Date of the transaction and date on which the threshold is crossed or reached (v): 17th April 2008 6. Date on which issued notified: 21st April 2008 7. Threshold(s) that is/are crossed or reached: 11% 8. Notified details A: Voting rights attached to shares Class/type of share if possible using the ISIN Code GB00B28XMY25 Situation Previous to the triggering transaction (vi) - Number of Shares 1,200,000 Number of Voting Rights (viii) 1,200,000 Resulting situation after the triggering transaction (viii) - Number of Shares 1,258,500 Number of Voting Rights - Direct (x) 1,258,500 Number of Voting Rights - Indirect (xi) N/A % of voting rights - Direct 11.28% % of voting rights - Indirect N/A B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of financial instrument N/A Expiration date (xiii) N/A Exercise/Conversion Period/Date (xiv) N/A Number of voting rights that may be acquired if theinstrument is exercised/converted N/A % of voting rights N/A Total (A+B) Number of voting rights 1,258,500 % of voting rights 11.28% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): STOCK IS REGISTERED IN GILTSPUR NOMINEES LIMITED Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: N/A 14. Contact name: Patrick Wilson 15. Contact telephone number: 028 90 446000 For further information: Percy LomaxReGen Therapeutics PlcTel: 020 7153 4920 Roland Cornish/Felicity GeidtBeaumont Cornish LimitedTel No 020 7628 3396 David Scott/Nick BealerAlexander David Securities LimitedTel: 020 7448 9800 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Apr 20204:40 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20207:00 amRNSNotice of GM
16th Apr 20209:05 amRNSSecond Price Monitoring Extn
16th Apr 20209:00 amRNSPrice Monitoring Extension
15th Apr 20204:31 pmRNSFurther Re: Block Listing Application
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSBlock Listing Application
15th Apr 20207:00 amRNSIssue of Equity
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:37 pmRNSPrice Monitoring Extension
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:01 amRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSTiziana Develops Treatment For COVID-19 Patients
16th Mar 20205:21 pmRNSClosing of Offer
12th Mar 20207:00 amRNSTiziana U.S. Follow-On Offering of $10 million
11th Mar 20207:00 amRNSTZLS-501 / COVID-19
20th Feb 202010:30 amRNSResult of GM
17th Feb 20207:00 amRNSProposed U.S. Public Offering of ADSs
4th Feb 202012:00 pmRNSDirector/PDMR Shareholding
3rd Feb 20207:00 amRNSNotice of GM
23rd Jan 20207:00 amRNSFiling of SEC Form F-3
21st Jan 20202:45 pmRNSDirector Appointment
14th Jan 202011:00 amRNSDirector/PDMR Shareholding
13th Jan 20207:00 amRNSProposed Cancellation from AIM
9th Jan 20207:00 amRNSFurther re: Foralumab Phase 1 Trial
2nd Jan 20203:00 pmRNSDirector/PDMR Shareholding
4th Dec 20197:00 amRNSForalumab Phase 1 Trial
20th Nov 20197:00 amRNSIssue of Equity and Directorate Change
1st Nov 20197:00 amRNSIssue of CLN
30th Oct 201910:31 amRNSChange to ADS ratio
30th Sep 20197:00 amRNSHalf-year Report
16th Sep 20197:00 amRNSFurther re: Update on IND Application
10th Sep 20197:00 amRNSPhase 1 Clinical Data
4th Sep 20197:00 amRNSPhase 2a Clinical Data
21st Aug 20194:40 pmRNSSecond Price Monitoring Extn
21st Aug 20194:35 pmRNSPrice Monitoring Extension
6th Aug 20197:00 amRNSProposed U.S. Public Offering
22nd Jul 20197:00 amRNSPhase 2a Clinical Data
1st Jul 20197:00 amRNSTeplizumab Article
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:35 pmRNSPrice Monitoring Extension
28th Jun 201910:54 amRNSChange of Adviser
25th Jun 20197:00 amRNSDirector/PDMR Shareholding
24th Jun 20197:00 amRNSArticle on Clinical Activity of OKT3
11th Jun 20197:00 amRNSDirector/PDMR Shareholding
7th Jun 20199:44 amRNSDirector/PDMR Shareholding
3rd Jun 20197:00 amRNSPDMR Dealings
31st May 201911:05 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.